A study reported the simultaneous infusion of T cells specific for tumor antigen (gp100, TRP1, or TRP2) and CAR-T cells against the mesenchymal vascular system (VEGFR-2), which yielded a synergistic effect on a mouse model of MEL eradication and improved tumor-free survival versus treatment with either cell type alone or with T cells that co-express the two target molecules [314] (Fig. 3). Here, PMEL is linked to neoplasm.